Fine-tuning miR-21 expression and inhibition of EMT in breast cancer cells using aromatic-neomycin derivatives.
EMT
breast cancer
epithelial to mesenchymal transition
miR-21
neomycin derivatives
non-coding RNAs
onco-miR
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
08 Mar 2022
08 Mar 2022
Historique:
received:
15
05
2020
accepted:
17
12
2021
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
25
1
2022
Statut:
epublish
Résumé
MicroRNAs (miRs) are a class of endogenously expressed non-coding RNAs that negatively regulate gene expression within cells and participate in maintaining cellular homeostasis. By targeting 3' UTRs of target genes, individual miRs can control a wide array of gene expressions. Previous research has shed light upon the fact that aberrantly expressed miRs within cells can pertain to diseased conditions, such as cancer. Malignancies caused due to miRs are because of the high expression of onco-miRs or feeble expression of tumor-suppressing miRs. Studies have also shown miRs to engage in epithelial to mesenchymal transition (EMT), which allows cancer cells to become more invasive and metastasize. miR-21 is an onco-miR highly expressed in breast cancer cells and targets protein PTEN, which abrogates EMT. Therefore, we discuss an approach where in-house-developed peptidic amino sugar molecules have been used to target pre-miR-21 to inhibit miR-21 biogenesis, and hence antagonize its tumor-causing effect and inhibit EMT. Our study shows that small-molecule-based fine-tuning of miR expression can cause genotypic as well as phenotypic changes and also reinstates the potential and importance of nucleic acid therapeutics.
Identifiants
pubmed: 35070496
doi: 10.1016/j.omtn.2021.12.027
pii: S2162-2531(21)00330-9
pmc: PMC8763640
doi:
Types de publication
Journal Article
Langues
eng
Pagination
685-698Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
D.P.A. has a financial interest in NUBAD LLC.
Références
Cell Res. 2008 Mar;18(3):350-9
pubmed: 18270520
RNA. 2008 Nov;14(11):2348-60
pubmed: 18812439
Oncogene. 2008 Apr 3;27(15):2128-36
pubmed: 17968323
Nat Rev Genet. 2007 May;8(5):341-52
pubmed: 17440531
Cancer Sci. 2012 Jun;103(6):1058-64
pubmed: 22435731
Bioorg Med Chem. 2017 Feb 15;25(4):1309-1319
pubmed: 28129992
Biomed Rep. 2016 Oct;5(4):395-402
pubmed: 27699004
Nature. 2007 Oct 11;449(7163):682-8
pubmed: 17898713
PLoS One. 2011;6(8):e22839
pubmed: 21829658
Eur J Cancer. 2010 May;46(7):1198-203
pubmed: 20303259
Mol Cancer. 2010 Jan 21;9:12
pubmed: 20092645
Genome Res. 2009 Jan;19(1):92-105
pubmed: 18955434
Medchemcomm. 2018 Jun 15;9(7):1147-1154
pubmed: 30109002
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60
pubmed: 15284443
Nucleic Acids Res. 2014 Jan;42(1):609-21
pubmed: 24068553
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Silence. 2012 Jan 09;3(1):1
pubmed: 22230293
Mol Ther Nucleic Acids. 2019 Dec 6;18:567-579
pubmed: 31678733
Nat Rev Cancer. 2006 Jun;6(6):449-58
pubmed: 16723991
Genome Biol. 2014 Apr 07;15(4):R57
pubmed: 24708865
Int J Oncol. 2016 Jan;48(1):161-72
pubmed: 26549725
Int J Mol Sci. 2019 Sep 23;20(19):
pubmed: 31547607
Methods Enzymol. 2019;623:291-314
pubmed: 31239051
Mol Ther Nucleic Acids. 2019 Dec 6;18:748-763
pubmed: 31733592
Nephrol Dial Transplant. 2009 Apr;24(4):1088-96
pubmed: 19145005
Nat Rev Cancer. 2003 Jun;3(6):453-8
pubmed: 12778135
Mol Ther Nucleic Acids. 2019 Dec 6;18:320-331
pubmed: 31614322
Mol Ther Nucleic Acids. 2019 Dec 6;18:627-637
pubmed: 31689617
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Mol Ther Nucleic Acids. 2019 Dec 6;18:308-319
pubmed: 31614321
Nat Rev Genet. 2010 Sep;11(9):597-610
pubmed: 20661255
Genes Dev. 2008 Apr 1;22(7):894-907
pubmed: 18381893
Anal Biochem. 2013 Mar 15;434(2):300-7
pubmed: 23262284
PLoS One. 2015 Dec 11;10(12):e0144251
pubmed: 26656788
Curr Genomics. 2009 May;10(3):154-68
pubmed: 19881909
Cancer Metastasis Rev. 2012 Dec;31(3-4):653-62
pubmed: 22684369
Br J Cancer. 2017 Mar 14;116(6):762-774
pubmed: 28152545
J Control Release. 2015 Dec 10;219:237-247
pubmed: 26256260
Bioorg Med Chem. 2014 Apr 1;22(7):2327-32
pubmed: 24630691
Biochemistry. 2019 Feb 12;58(6):514-525
pubmed: 30585723
Oncol Rep. 2006 Feb;15(2):291-6
pubmed: 16391844
J Clin Med. 2017 Dec 22;7(1):
pubmed: 29271928
Mol Ther Nucleic Acids. 2019 Dec 6;18:110-122
pubmed: 31541797
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
PLoS One. 2014 Feb 25;9(2):e89019
pubmed: 24586483
Nat Rev Genet. 2011 Feb;12(2):99-110
pubmed: 21245828
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Cell Biol. 2008 May;10(5):593-601
pubmed: 18376396
Int J Mol Sci. 2013 Oct 16;14(10):20768-92
pubmed: 24135872
Viruses. 2012 Oct 26;4(11):2485-513
pubmed: 23202492
Nature. 2008 Jan 10;451(7175):147-52
pubmed: 18185580
Chem Sci. 2015 Oct 1;6(10):5837-5846
pubmed: 29861909
Antimicrob Agents Chemother. 2015 Jul;59(7):3899-905
pubmed: 25896697
ACS Chem Biol. 2015 May 15;10(5):1278-89
pubmed: 25706406
Nature. 2010 Sep 2;467(7311):86-90
pubmed: 20693987
Org Biomol Chem. 2016 Feb 14;14(6):2052-6
pubmed: 26765486
Mol Ther Nucleic Acids. 2017 Sep 15;8:132-143
pubmed: 28918016
Biochemistry. 2016 Dec 20;55(50):7023-7032
pubmed: 27992999
J Biomed Sci. 2015 Jan 23;22:9
pubmed: 25614041
Eur J Med Chem. 2019 Feb 1;163:381-393
pubmed: 30530174